Grant: CIHR Fellowship
Direct Payment
$150,000.00
Genetic and metagenomic study of digoxin metabolism by Eggerthella lenta and other members of the human gastrointestinal microbiota.
EF 2010-11
Résumé
Within recent years, there has been an increasing appreciation for the role played by the microorganisms living in, and on the human body. This includes the "gut microbiota", the diverse and abundant group of microorganisms that colonize the human gastrointestinal tract. Collectively, the genes of the microbiota are referred to as the "microbiome". Recent technological advancements have made it possible to begin studying the microbiome, and its role in human health and disease states. The gut microbiota prevent the growth of disease-causing bacteria, help extract nutrients from our diet, and also play a role in certain intestinal diseases. It has become abundantly clear that in order to fully understand human metabolism, we must consider the contributions of the gut microbiome. One such contribution is the chemical modification of orally ingested therapeutic drugs from active, to inactive forms. Importantly, the unexpected alteration of drug concentrations by the microbiota can adversely affect treatment. As such, this study will examine the metabolism of a commonly prescribed heart medication named "digoxin" by a member of the gut microbiota, Eggerthella lenta. We will harness cutting-edge techniques to identify the genes involved in the metabolism of digoxin by E. lenta. These findings will then allow us to identify other members of the gut microbiota able to carry out this same chemical reaction. Additionally, using mouse models, we will investigate whether dietary changes affect the ability of the gut microbiota to metabolize digoxin. By providing a more complete understanding of digoxin metabolism, this work will lead to improved therapeutic strategies for treating heart disease. Our investigation will also serve as a landmark study, the findings of which will be broadly applicable to future drug discovery protocols incorporating the role of the gut microbiota.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
214381
Name
Haiser Henry J
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Genetic and metagenomic study of digoxin metabolism by Eggerthella lenta and other members of the human gastrointestinal microbiota.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Human Microbiome; Metagenomics; Therapeutic Drug Metabolism; Transcriptomics
Abstract
Within recent years, there has been an increasing appreciation for the role played by the microorganisms living in, and on the human body. This includes the "gut microbiota", the diverse and abundant group of microorganisms that colonize the human gastrointestinal tract. Collectively, the genes of the microbiota are referred to as the "microbiome". Recent technological advancements have made it possible to begin studying the microbiome, and its role in human health and disease states. The gut microbiota prevent the growth of disease-causing bacteria, help extract nutrients from our diet, and also play a role in certain intestinal diseases. It has become abundantly clear that in order to fully understand human metabolism, we must consider the contributions of the gut microbiome. One such contribution is the chemical modification of orally ingested therapeutic drugs from active, to inactive forms. Importantly, the unexpected alteration of drug concentrations by the microbiota can adversely affect treatment. As such, this study will examine the metabolism of a commonly prescribed heart medication named "digoxin" by a member of the gut microbiota, Eggerthella lenta. We will harness cutting-edge techniques to identify the genes involved in the metabolism of digoxin by E. lenta. These findings will then allow us to identify other members of the gut microbiota able to carry out this same chemical reaction. Additionally, using mouse models, we will investigate whether dietary changes affect the ability of the gut microbiota to metabolize digoxin. By providing a more complete understanding of digoxin metabolism, this work will lead to improved therapeutic strategies for treating heart disease. Our investigation will also serve as a landmark study, the findings of which will be broadly applicable to future drug discovery protocols incorporating the role of the gut microbiota.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Haiser, Henry J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~